Amendments to the Specification

Please replace the Sequence Listing filed February 25, 2005, with the Substitute Sequence Listing filed herewith.

Please replace Table 2 on page 23 with the following Table 2:

Table 2

hsp105-derived peptides

hsp105-derived peptides			
No.	Position	Sequence	Binding Score
1	hsp105 180-188	NYGIYKQDL (SEQ ID NO: 3)	2400
2	hsp105 214-223	AFNKGKLKVL (SEQ ID NO: 4)	960
3	hsp105 251-260	KYKLDAKSKI (SEQ ID NO: 5)	2880
4	hsp105 305-313	QFEELCAEL (SEQ ID NO: 6)	1382
5	hsp105 433-442	TFLRRGPFEL (SEQ ID NO: 8)	1920
6	hsp105 570-579	MYIETEGKMI (SEQ ID NO: 7)	4800
7	hsp105 597-606	ECVYEFRDKL (SEQ ID NO: 23)	80
8	hsp105 682-690	HYAKIAADF (SEQ ID NO: 10)	60
9	hsp105 696-705	KYNHIDESEM (SEQ ID NO: 11)	432

Please replace the paragraph on page 25, between lines 8 and 19 with the following amended paragraph:

<Determination of CTL epitope peptide of hsp105>

In order to identify a CTL epitope peptide, pancreatic cells were recovered from the mice, on which the DNA vaccine-peptide vaccine had worked. The recovered cells were stimulated once with the 9 types of peptides shown in Table 2, and the cytotoxic activity on Colon-26 was analyzed by ^{51}Cr release assay. As a result, it was found that among the above-described 9 types of peptides, the following 5 types of peptides 1, 2, 3, 4, and 5 are useful (Figure 4).

Asn-Tyr-Gly-Ile-Tyr-Lys-Gln-Asp-Leu	(1)	(SEQ ID NO: 3)
Ala-Phe-Asn-Lys-Gly-Lys-Leu-Lys-Val-Leu	(2)	(SEQ ID NO: 4)
Lys-Tyr-Lys-Leu-Asp-Ala-Lys-Ser-Lys-Ile	(3)	(SEQ ID NO: 5)
Gln-Phe-Glu-Glu-Leu-Cys-Ala-Glu-Leu	(4)	(SEQ ID NO: 6)
Met-Tyr-Ile-Glu-Thr-Glu-Gly-Lys-Met-Ile	(5)	(SEQ ID NO: 7)

Please replace Table 3 on page 27 with the following Table 3, attached as a separate sheet.

Table 3: Peptides which can induce peptide-specific and cancer cell cytotoxic killer T cell by stimulating human peripheral blood lymphocytes of HLA-A24

hsp105-derived peptide	Position	Sequence	HLA-A2402-binding score	Each peptide-induced CTLs from Pt 1 (HLA-A2402/) % Lysis to (HLA-A 0201/2402) peptide 10μM			Each peptide-induced CTLs from Pt 2 (HLA-A2402/) % Lysis to (HLA-A0201) peptide 10μM		
				sw620	C1RA2402	C1RA2402	sw620	C1RA2402	C1RA2402
A24-1	180-188	NYGIYKQDL (SEQ ID NO: 3)	240	16	42	31	32	13	25
A24-2	214-223	AFNKGKLKVL (SEQ ID NO: 4)	30	0	42	49	40	28	54
A24-3	251-260	KYKLDAKSKI (SEQ ID NO: 5)	110	50	29	46	21	33	44
A24-4	305-313	QFEELCAEL (SEQ ID NO: 6)	48	48	22	43	16	40	38
A24-5	433-442	TFLRRGPFEL (SEQ ID NO: 8)	33	53	33	33	26	33	46
A24-6	613-622	MYIETEGKMI (SEQ ID NO: 7)	90	49	22	47	29	28	52
A24-7	640-649	EYVYEFRDKL (SEQ ID NO: 9)	330	40	22	45	8	26	31
A24-8	725-733	HYAKIAADF (SEQ ID NO: 10)	140	41	25	37	66	28	43
A24-9	739-748	KYNHIDESEM (SEQ ID NO: 11)	83	19	36	43	33	24	45

Please replace Table 4 on page 29 with the following Table 4, attached as a separate sheet.

Table 4: Peptides which can induce peptide-specific and cancer cell cytotoxic killer T cell by stimulating human peripheral blood lymphocytes of HLA-A2. Sequences A2-1 to A2-7, A2-9, A2-10, A2-14, A2-16 to A2-19, A2-21, A2-22, A2-24, A2-28, and A2-29 are as disclosed in SEQ ID NO: 1.

hsp105-derived peptide	Position	Sequence	HLA-A2401-binding score	each peptide-induced CTLs from Pt 1 (HLA-A0207/3301) % Lysis to sw620 (HLA-0201)	sw620 hsp105-RNAi	sw620 hsp105-RNAi peptide 10μM	each peptide-induced CTLs from HD 1 (HLA-A0201/0207) % Lysis to sw620 (HLA-A0201)	sw620 hsp105-RNAi	sw620 hsp105-RNAi peptide 10μM
A2-1	86-94	NLSYDLVPL	49	5	68	56	-	-	-
A2-2	103-111	VMYMGEEHL	41	20	41	36	-	-	-
A2-3	105-114	YMGEEHLFSV	12637	5	0	0	-	-	-
A2-4	120-128	MLLTKLKET	107	0	0	1	6	35	3
A2-5	141-149	VISVPSFFT	55	4	0	5	-	-	-
A2-6	155-163	SVLDAAQIV	37	5	7	18	4	0	13
A2-7	169-177	RLMNDMTAV	591	4	0	8	2	29	32
A2-8	190-199	SLDEKPRIVV (SEQ ID NO: 12)	46	30	18	0	26	9	40
A2-9	202-210	DMGHSAFQV	21	26	0	3	-	-	-
A2-10	222-231	VLGTAFDPFL	759	0	29	20	2	0	0
A2-11	265-273	RLYQECEKL (SEQ ID NO: 13)	33	18	0	28	15	0	17
A2-12	275-284	KLMSSNSTDL (SEQ ID NO: 14)	276	10	1	13	10	28	58
A2-13	276-284	LMSSNSTDL (SEQ ID NO: 15)	26	11	0	21	11	0	14
A2-14	300-309	KMNRSQFEEL	50	11	0	0	44	61	9
A2-15	304-313	SQFEELCAEL (SEQ ID NO: 16)	32	12	0	4	21	0	9
A2-16	313-321	LLQKIEVPL	36	10	21	8	-	-	-
A2-17	323-332	SLLEQTHLKV	1055	1	76	34	32	0	0
A2-18	381-389	AILSPAFKV	205	50	0	0	22	28	9
A2-19	434-442	FLRRGPFEL	43	8	39	3	-	-	-
A2-20	458-467	KIGRFVVQNV (SEQ ID NO: 17)	76	24	0	9	32	9	4
A2-21	601-610	NLVWQLGKDL	21	7	0	4	5	0	4
A2-22	602-610	LVWQLGKDL	26	19	0	3	-	-	-
A2-23	641-649	YVYEFRDKL (SEQ ID NO: 18)	210	26	2	13	0	9	23
A2-24	648-657	KLCGPYEKFI	200	9	0	0	42	0	9
A2-25	668-676	LLTETEDWL (SEQ ID NO: 19)	401	32	0	27	23	42	27
A2-26	675-684	WLYEEGEDQA (SEQ ID NO: 20)	146	18	0	41	11	21	3
A2-27	694-702	ELMKIGTPV (SEQ ID NO: 21)	19	14	0	13	22	0	0
A2-28	714-723	KMFEELGQRL	819	11	2	0	5	0	0
A2-29	757-765	EVMEWMNNV	15	1	0	0	-	-	-
A2-30	765-774	VMNAQAKKSL (SEQ ID NO: 22)	26	0	0	11	26	0	12